ESMO Congress 2026
October 23–27, 2026 · Madrid · 4468 items
atezolizumab
5 people · 5 posts
Heat trend for this story
Heat now 1·Peak in the comparable set 1 (Oct 26 19:00)·Change over 24h in the comparable set –·Participants now 2
Participants counted2
Heat over time
Deep dive
Atezolizumab is an anti-PD-L1 monoclonal antibody whose phase 3 evidence is well established across multiple solid tumors: the OAK trial versus docetaxel in previously treated NSCLC [4], IMpower150 evaluating atezolizumab plus bevacizumab plus chemotherapy in first-line metastatic nonsquamous NSCLC [6], IMpassion130 testing atezolizumab plus nab-paclitaxel in advanced triple-negative breast cancer [5], and IMbrave150 versus sorafenib in unresectable hepatocellular carcinoma with a death hazard ratio of 0.58 (95% CI 0.42–0.79) [1], which also placed the combination on the list of HCC systemic therapies approved based on phase III trials [2]. On the mechanistic side, data from a metastatic urothelial cancer cohort showed response associated with the CD8+ T-effector phenotype and high tumor mutation burden, and resistance associated with a fibroblast TGFβ signature [3].
Two readouts for this asset appeared at the meeting. First, the final analysis of the phase 3 BEATcc trial (n=410): adding atezolizumab to chemotherapy plus bevacizumab maintained the overall survival benefit in first-line metastatic, persistent or recurrent cervical cancer, with a median follow-up of 57.2 months, OS of 31.9 vs 22.7 months, HR 0.69 (95% CI 0.54–0.88), 4-year OS of 40% vs 26%, an absolute difference of 14 percentage points, and second progression-free survival of 23.3 vs 17.0 months, HR 0.62 (95% CI 0.49–0.78). Second, SWOG S2200 (PAPMET2) randomized cabozantinib ± atezolizumab in metastatic papillary RCC; the trial closed early for slow accrual with 33 eligible patients: mPFS 25 vs 10 months, HR 0.46 (95% CI 0.22–0.97), p=0.043; ORR 47% vs 19%; PD as best response 0% vs 19%; grade 3/4 AEs 65% vs 75%. The presenter argued that despite the small sample and early closure, these randomized data still support IO/TKI combination as an appropriate first-line strategy.
The site news did not repeat either readout but independently reported a different thread: a Jackson Laboratory team published in Science that long-read RNA sequencing identified thousands of previously unknown STAT2 splice variants in lung cancer, among which intron-retaining STAT2 was associated with longer survival on atezolizumab treatment, validated using data from two large clinical trials; the splice signature can potentially identify patients who benefit from immunotherapy, and the team has filed a provisional patent for correcting splicing errors and predicting response. This belongs to the biomarker dimension of response prediction, complementing rather than duplicating the efficacy endpoints on site, so consistency with the live data is not at issue.
In terms of advancement, the final BEATcc analysis with 57.2 months of follow-up confirms the durability of the first-line cervical cancer benefit and adds the deeper-line signal of second progression-free survival, while PAPMET2 brings randomized evidence for atezolizumab plus a TKI into papillary RCC—where previously published phase 3 evidence was concentrated in HCC, NSCLC and triple-negative breast cancer [1][4][5][6]. The limitations are equally clear: PAPMET2 had only 33 patients and closed early, limiting statistical power; the BEATcc figures come from an on-site relay, with details to be confirmed in the full publication; and the predictive value of the STAT2 splicing signature still awaits prospective validation.
References
- 1.Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma · N Engl J Med 2020
- 2.Hepatocellular carcinoma · Nat Rev Dis Primers 2021
- 3.TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells · Nature 2018
- 4.Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial · Lancet 2017
- 5.Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer · N Engl J Med 2018
- 6.Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC · N Engl J Med 2018
Floor
x.com@ Minhua Chu@chuminhua432 GI Oncology Now@GiOncNow Rashid K. Sayyid@RKSayyid #ESMO26 Can adding atezolizumab to cabozantinib improve outcomes in metastatic papillary RCC?
ScienceLink@sciencelinkonco #ScienceLink #Madrid2026 #ESMO26 #BEATcc #atezolizumab
Same topic atezolizumab · 5 peoplebevacizumab#SCIENCELINK#MADRID2026#BEATCC#ATEZOLIZUMAB3 views0 likes0 reposts0 repliesFDA DrugsPick FDA approves atezolizumab in combination with chemotherapy for Stage III mismatch repair deficient colon cancer
The FDA approved atezolizumab (Tecentriq, Genentech) in combination with a fluoropyrimidine and oxaliplatin on October 8, 2026, for adjuvant treatment of Stage III mismatch repair deficient colon cancer in patients two years of age and older, with the subcutaneous Tecentriq Hybreza approved for those 12 years and older weighing 40 kg or greater. In the ATOMIC trial of 711 adults and one pediatric patient, the hazard ratio for disease-free survival was 0.50 versus mFOLFOX6 alone, and median DFS was not reached in either arm. Reviews are ongoing at partner agencies under Project Orbis.
Why it matters: FDA approval of atezolizumab plus chemotherapy as adjuvant therapy for Stage III dMMR colon cancer, with a disease-free survival hazard ratio of 0.50.
Same topic atezolizumab · 18 peopleNo engagement yetdoi.org At-home subcutaneous atezolizumab for non-small cell lung cancer: a prospective, single-arm phase II feasibility study
Same topic atezolizumab · 18 peopleNo engagement yetLung Cancer ManagPick At-home subcutaneous atezolizumab for non-small cell lung cancer: a prospective, single-arm phase II feasibility study
A prospective, single-arm phase II feasibility study enrolled five patients with NSCLC to assess the safety and feasibility of at-home subcutaneous atezolizumab (1,875 mg every 21 days). Of 70 treatment cycles, 65 injections (93%) were delivered on time. Home administration took a mean of 42.3 minutes versus 86.7 minutes in clinic. Two of five patients (40%) had adverse events, and mean patient satisfaction with administration was 3.3/4.
Why it matters: Phase II feasibility study reports first data on at-home subcutaneous atezolizumab in NSCLC.
Same topic atezolizumab · 18 peopleNo engagement yetthelancet.com [Comment] Combining immunotherapy with stereotactic body radiation therapy in localised non-small-cell lung cancer
A comment published alongside The Lancet discusses the phase 3 SWOG/NRG S1914 randomised trial led by Megan E Daly and colleagues in the USA. The trial tested whether perioperative atezolizumab, given neoadjuvantly, concurrently and as adjuvant, with stereotactic body radiation therapy improves outcomes in high-risk, medically inoperable early-stage non-small-cell lung cancer. Its primary endpoint compares overall survival in 210 patients given atezolizumab plus SBRT versus 207 given SBRT alone.
Same topic atezolizumab · 18 peopleNo engagement yetLancet Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial.
Same topic atezolizumab · 18 peopleNo engagement yetNat MedPick Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial.
Adding atezolizumab to neoadjuvant taxane-carboplatin-anthracycline chemotherapy did not significantly improve event-free survival in stage II-III triple-negative breast cancer, with an HR of 0.80 (95% CI, 0.62-1.03; P = 0.083) and a 4-year EFS difference of 3.3%. Prespecified subgroup analysis suggested benefit in patients with clinical lymph node involvement (P interaction = 0.039), and an exploratory mRNA subset analysis pointed to basal-like immune-activated tumors as potential responders. Immune-related adverse events occurred in 27.6% with atezolizumab versus 11.4% with placebo.
Why it matters: Negative phase 3 result for checkpoint inhibition in early TNBC, with subgroup data pointing to who might still benefit.
Same topic atezolizumab · 18 peopleNo engagement yetThe LancetPick [Articles] Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial
Adding induction and consolidation atezolizumab to stereotactic body radiation therapy did not improve overall survival in patients with high-risk, inoperable, early-stage non-small-cell lung cancer in the SWOG/NRG S1914 phase 3 randomised trial. This was the first fully reported phase 3 cooperative group trial of immunotherapy in this setting, and the combination produced more grade 3 or higher adverse events than radiation alone. The results argue against adding atezolizumab to SBRT in this population.
Why it matters: First fully reported phase 3 trial of immunotherapy in inoperable early-stage NSCLC, and it was negative.
Same topic atezolizumab · 18 peopleNo engagement yetLancetPick Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial.
Liver resection after response to atezolizumab plus bevacizumab prolonged time to treatment failure in advanced hepatocellular carcinoma with macrovascular invasion and no extrahepatic metastasis. In the phase 3 TALENTOP trial, 201 responders were randomised to surgery plus 12 months of the combination or maintenance therapy; median time to treatment failure was 20·4 versus 11·8 months (hazard ratio 0·60, p=0·015). Grade 3 or 4 treatment-related adverse events were more frequent with surgery (39% vs 21%).
Why it matters: Randomised phase 3 evidence that resection adds benefit after systemic therapy in advanced hepatocellular carcinoma.
nature.comPick Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial
Adding atezolizumab to neoadjuvant chemotherapy did not improve event-free survival in the phase 3 NSABP B-59/GeparDouze trial of patients with early-stage triple-negative breast cancer, missing its primary endpoint. Translational analyses identified tumor microenvironment-dependent determinants of response, indicating basal-like immune-activated tumors may respond to atezolizumab plus chemotherapy.
Why it matters: Negative phase 3 result for atezolizumab in early triple-negative breast cancer, with biomarker data indicating which tumors may still benefit.
Same topic atezolizumab · 18 peopleNo engagement yetJAMA Oncology Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in ES-SCLC
Same topic atezolizumab · 18 peopleNo engagement yetaacr.org Clinical Trial Results: Long-term Updates on Approved Immunotherapies
A record 265 clinical trial abstracts fed five minisymposia. The 'Updates in Anticancer Immunotherapies' session covered atezolizumab in alveolar soft part sarcoma: 54 patients enrolled as of June 2025, with responses lasting 10 to 69 months.
Same topic atezolizumab · 18 peopleNo engagement yetmedicalxpress.comPick Overlooked 'off switch' in lung tumors may explain why immunotherapy doesn't work for everyone
A Jackson Laboratory team publishing in Science used long-read RNA sequencing to identify thousands of previously unrecognized STAT2 splicing variants in lung cancer. Intron-retaining STAT2 was associated with longer survival on the anti-PD-L1 drug atezolizumab, validated with data from two large clinical trials. The splicing signature could potentially identify patients likely to benefit from immunotherapy, and the team has filed a provisional patent for correcting splicing errors and predicting response (DOI: 10.1126/science.aea7156).
Why it matters: Intron retention in STAT2 splicing predicts lung cancer immunotherapy response, validated by long-read sequencing and clinical trial data.
Same topic atezolizumab · 18 peopleNo engagement yetmp.weixin.qq.com FDA Approves Roche's Tecentriq as Adjuvant Therapy for Stage III dMMR Colon Cancer
The US FDA has approved Roche's Tecentriq (atezolizumab) and its subcutaneous formulation Tecentriq Hybreza (atezolizumab and hyaluronidase), each combined with fluoropyrimidine and oxaliplatin, as post-surgery adjuvant treatment for stage III mismatch repair-deficient (dMMR) colon cancer. Roche said this is the first immunotherapy adjuvant approval for stage III dMMR colon cancer in the US, based on data showing a 50% reduction in risk of disease recurrence or death.
Same topic atezolizumab · 18 peopleNo engagement yetmp.weixin.qq.com FDA Approves Atezolizumab for dMMR Stage III Colon Cancer and Tucatinib for HER2-Positive Breast Cancer
On October 8, 2026, the FDA approved atezolizumab (Tecentriq, Genentech) combined with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III mismatch repair-deficient (dMMR) colon cancer in adults and children aged 2 and older. In the same window, the FDA also approved tucatinib maintenance therapy for HER2-positive breast cancer. On the same day, China's CDE released two draft guidances for comment, covering GVHD clinical trials and nonclinical PK studies.
Same topic tucatinib · 18 peopleNo engagement yetmp.weixin.qq.com FDA Approves IV and Subcutaneous Tecentriq for Stage III dMMR Colon Cancer Adjuvant Therapy
On October 8, 2026, the FDA approved Genentech/Roche's atezolizumab (Tecentriq), given intravenously with fluoropyrimidine plus oxaliplatin chemotherapy, as adjuvant treatment after surgery for stage III mismatch repair-deficient (dMMR) colon cancer in adults and children aged 2 and older. The subcutaneous formulation Tecentriq Hybreza, atezolizumab with hyaluronidase-tqjs, was also approved with the same chemotherapy for patients aged 12 or older weighing at least 40 kg. These are Tecentriq's second US indication expansions this year, after its approval months earlier for Signatera ctDNA-positive muscle-invasive bladder cancer.
Same topic atezolizumab · 18 peopleNo engagement yetOncoimmunologyPick Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer
Earlier infusions of first-line platinum-etoposide plus atezolizumab or durvalumab were linked to longer survival in 107 patients with extensive-stage small cell lung cancer. Those treated before the cohort median time of day of administration (11:54) had median PFS of 9.07 vs. 7.23 months and OS of 21.17 vs. 11.43 months, with adjusted HRs of 1.63 and 1.65 for later administration, and no difference in toxicity. The finding points to infusion timing as a modifiable factor that warrants prospective testing.
Why it matters: It provides independent validation that circadian infusion timing affects checkpoint inhibitor outcomes in ES-SCLC.
Same topic atezolizumab · 18 peopleNo engagement yetmedRxiv OncologyPick Incremental Predictive Value and Representation of Transcriptomic Features for Immunotherapy Response in Advanced Urothelial Carcinoma
Knowledge-guided tumor microenvironment gene-set features outperform data-driven transcriptome-wide gene selection for predicting atezolizumab response in advanced urothelial carcinoma. In 298 IMvigor210 patients, they improved AUPRC by 0.058 over clinical variables, but gains shrank to +0.011 beyond TMB and PD-L1, and data-driven selection was unstable (Jaccard 0.227) with AUPRC 0.150 lower. The pattern replicated in an external cohort (+0.128 vs +0.019).
Why it matters: Quantifies how little transcriptomics adds beyond standard biomarkers for immunotherapy prediction in advanced urothelial carcinoma.
Same topic atezolizumab · 18 peopleNo engagement yet